

DOCKET NO.: CELG-0119



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Vikram Khetani, et al.

Confirmation No.: 1269

Application No.: 09/283,645

Group Art Unit: 1625

Filing Date: April 1, 1999

Examiner: Celia C. Chang

**For: PROCESS AND INTERMEDIATES FOR RESOLVING PIPERIDYL
ACETAMIDE STEROISOMERS**

**EXPRESS MAIL LABEL NO: EL 999283857 US
DATE OF DEPOSIT: June 7, 2005**

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

☒ Copies of reference numbers 1-14 listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

There are no listed references which are not in the English language.


DOCKET NO.: CELG-0119

- 3 -

PATENT

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: June 7, 2005


A handwritten signature in black ink, appearing to read 'Walter C. Frank', is written over a horizontal line.

Walter C. Frank

Registration No. 52,911

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2005 WW




Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CELG-0119	Application No. 09/283,645
	Applicant Khetani, et al.	
	Filing Date April 1, 1999	Group 1625
	Confirmation No. 1269	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	Aoyama, T., et al., "Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers," <i>Eur. J. Clin. Pharmacol.</i> , 1993 , 44, 79-84
2	Barkley, R. A., et al., "The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study," <i>J. Am. Acad. Adolesc. Psychiatry.</i> , 1990 , 29(4), 546-557
3	Bruera, E., and Neumann, C. M., "The uses of psychotropics in symptom management in advanced cancer," <i>Psycho-Oncology.</i> , 1998 , 7, 346-358
4	Garland, E. J., "Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats," <i>J. Psychopharmacology.</i> , 1998 , 12(4), 385-395
5	Golden, G. S., "Role of attention deficit hyperactivity disorder in learning disabilities," <i>Seminars in Neurology.</i> , 1991 , 11(1), 35-41
6	Goldman, L. S., et al., "Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents," <i>J. Am. Med. Assn.</i> , 1998 , 279(14), 1100-1107
7	No author, " <i>Methylphenidate hydrochloride</i> ," Environmental Health Perspectives, 1997 , 105 (supp 1), 319
8	Patrick, K. S., et al., "Pharmacology of the enantiomers of <i>threo</i> -methylphenidate," <i>J. Pharmacol. Expt Ther.</i> , 1987 , 241, 152-158
9	Spencer, T., et al., "Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle," <i>J. Am. Acad. Adolesc. Psychiatry.</i> , 1996 , 35(4), 409-432
10	Srinivas, N. R., et al., "Enantioselective pharmacokinetics and pharmacodynamics of <i>d,l-threo</i> -methylphenidate in children with attention deficit hyperactivity disorder," <i>Clin. Pharmacol. Ther.</i> , 1992 , 52(5), 561-568
11	Stein, M. A., et al., "Methylphenidate dosing: Twice daily versus three times daily," <i>Pediatrics.</i> , 1996 , 98(4), 748-756

EXAMINER

DATE CONSIDERED



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CELG-0119	Application No. 09/283,645
	Applicant Khetani, et al.	
	Filing Date April 1, 1999	Group 1625
	Confirmation No. 1269	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
12	Swanson, J. M., et al., "Analog classroom assessment of Adderall in children with ADHD," <i>J. Am. Acad Child Adolesc. Psychiatry.</i> , 1998 , 37(5), 519-525	
13	Ward, M. F., et al., "The Wender Utah rating scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder," <i>Am. J. Psychiatry.</i> , 1993 , 150(6), 885-890	
14	Zametkin, A. J. and Ernst, M., "Problems in the management of attention-deficit/hyperactivity disorder," <i>New. Eng. Jour. Med.</i> , January 1999 , 340(1), 40-46	

© 2005 WW

EXAMINER

DATE CONSIDERED